Cardiometabolic Drugs Market Share

North American Market Forecast

North America industry is expected to dominate majority revenue share by 2037, on the back of the presence of multiple key players in the market in the region and a higher prevalence of cardiovascular diseases and usage of cardiovascular devices. Centers for Disease Control and Prevention released data which revealed that in 2019, about 360,900 people died due to coronary heart disease, meanwhile, 1 person loses his life every 36 seconds due to heart disease in the United States. Furthermore, the North American region is projected to be the second-highest number of diabetes patients which in turn is projected to increase the sales of cardiometabolic drugs in the forecast period. According to the report from the National Institute of Diabetes and Digestive and Kidney Diseases, in 2020, 10.5% of the U.S. population had diabetes while an additional 8.2% of people were diagnosed with diabetes.

APAC Market Statistics

Furthermore, the global cardiometabolic drugs market is also projected to grow at a significant pace in the Asia-Pacific region during the forecast period. The growth of the market in the region can be attributed to similar factors, such as rising cases of cardiovascular diseases and a growing geriatric population with various types of diseases and disorders. Also, the rapid growth of the healthcare industry and rising investment in enhancing the healthcare system are other factors that are anticipated to create a positive outlook for generating significant revenue in the forecast period.